Other languages Lexaria Bioscience Corp.

Equities

LEXX

US52886N4060

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
2.19 ^USD	-0.45%		-2.67%	+75.20%

Apr. 16	Lexaria Obtains Ethics Review Board Approval to Start New GLP-1 Study	MT
Apr. 16	Lexaria Bioscience Corp. Receives Ethics Review Board Approval to Begin New GLP-1 Study	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lexaria Bioscience Corp. Receives Ethics Review Board Approval to Begin New GLP-1 Study	Apr. 16
Lexaria Bioscience Corp. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	Apr. 09
Lexaria Bioscience Corp. Receives New Patents in the Fields of Epilepsy and Anti-Viral Agents	Apr. 02
Lexaria Bioscience Names Nelson Cabatuan as Finance Chief	Mar. 14
Sector Update: Health Care Stocks Retreating Late Afternoon	Mar. 05
Sector Update: Health Care	Mar. 05
Lexaria Bioscience to Start Diabetes, Weight Loss Animal Study; Shares Rise	Mar. 05
Lexaria to Begin Diabetes and Weight Loss Animal Study Well-A24-1	Mar. 05
Lexaria Bioscience Corp. Signs Contracts to Begin Animal Study Well-A24-1	Mar. 04
Lexaria Bioscience Corp. Announces 7% Weight Loss in Animals Supports in its Next 8-Week Animal Study	Mar. 04
Lexaria Bioscience Corp. Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial	Mar. 01
Lexaria Bioscience Corp. Submits Investigational New Drug Application	Jan. 30
Lexaria Bioscience Corp. Unveils Extensive Planned 2024 GLP-1 Study Program	Jan. 16
Lexaria Bioscience Corp. Reports Earnings Results for the First Quarter Ended November 30, 2023	Jan. 12
Lexaria Bioscience Corp. Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream	Jan. 11
Lexaria Bioscience Corp. Improves Delivery, Efficacy of Glp-1 Agonists Through Proprietary Drug-Delivery Platform	Jan. 09
Lexaria Bioscience Corp. Announces Positive Final Results from its Recently Completed Human Pilot Study #1 for the Oral Performance of the Rybelsus(R)-Branded GLP-1 Drug Semaglutide	Jan. 04
Lexaria Bioscience Set to File Investigational New Drug Application for Hypertension Trial Within 45 Days	Dec. 07
Lexaria Bioscience Corp. Announces Investigational New Drug Application Filing Update	Dec. 07
Lexaria's Technology Improves the Oral Performance of the Rybelsus(R-Branded GLP-1 Drug Semaglutide in Human Pilot Study	Nov. 27

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Lexaria Bioscience Corp.

Equities

LEXX

US52886N4060

Other languages

Filters